Fluocinolone acetonide
Clinical data | |
---|---|
Trade names | Synalar, Iluvien, others |
AHFS/Drugs.com | Monograph Monograph |
Pregnancy category |
|
Routes of administration | Topical, ophthalmic intravitreal injection |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Liver, CYP3A4-mediated |
Elimination half-life | 1.3 to 1.7 hours |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Fluocinolone acetonide is a corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching.[citation needed] It is a synthetic hydrocortisone derivative. The fluorine substitution at position 9 in the steroid nucleus greatly enhances its activity. It was first synthesized in 1959 in the Research Department of Syntex Laboratories S.A. Mexico City.[2] Preparations containing it were first marketed under the name Synalar. A typical dosage strength used in dermatology is 0.01–0.025%. One such cream is sold under the brand name Flucort-N and includes the antibiotic neomycin.
Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated chondrogenesis of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.[3]
Fluocinolone acetonide
It was approved for medical use in 1961.[6]
Classification
Fluocinolone is a group V (0.025%) or group VI (0.01%) corticosteroid under US classification.
Society and culture
Brand names
Yutiq.[7]
References
- ^ "Regulatory Decision Summary for Iluvien". Drug and Health Product Portal. Health Canada. 23 October 2014.
- .
- PMID 25753754.
- PMID 37642198.
- ^ "Real-world study shows long-term safety, efficacy of Iluvien in DME". Healio. 2020-07-02. Retrieved 2020-10-28.
- ISBN 9783527607495.
- ^ "Yutiq- fluocinolone acetonide implant". DailyMed. 16 October 2023. Retrieved 25 December 2023.